Poster Print Size: This poster template is 24” high by 48” wide. It can be used to print any poster with a 1:2 aspect ratio including 30x60, 36x72, 42x84, and 48x96. Placeholders: The various elements included in this poster are ones we often see in medical, research, and scientific posters. Feel free to edit, move, add, and delete items, or change the layout to suit your needs. Always check with your conference organizer for specific requirements. Image Quality: You can place digital photos or logo art in your poster file by selecting the Insert, Picture command, or by using standard copy & paste. For best results, all graphic elements should be at least pixels per inch in their final printed size. For instance, a 1600 x 1200 pixel photo will usually look fine up to 8“-10” wide on your printed poster. To preview the print quality of images, select a magnification of 100% when previewing your poster. This will give you a good idea of what it will look like in print. If you are laying out a large poster and using half-scale dimensions, be sure to preview your graphics at 200% to see them at their final printed size. Please note that graphics from websites (such as the logo on your hospital's or university's home page) will only be 72dpi and not suitable for printing. [This sidebar area does not print.] Change Color Theme: This template is designed to use the built-in color themes in the newer versions of PowerPoint. To change the color theme, select the Design tab, then select the Colors drop-down list. The default color theme for this template is “Office”, so you can always return to that after trying some of the alternatives. Printing Your Poster: Once your poster file is ready, visit to order a high-quality, affordable poster print. Every order receives a free design review and we can deliver as fast as next business day within the US and Canada. Genigraphics® has been producing output from PowerPoint® longer than anyone in the industry; dating back to when we helped Microsoft® design the PowerPoint® software. US and Canada: [This sidebar area does not print.] Use of High-Dose Omega-3 Fatty Acids to Treat Macular Dystrophies. Tassos Georgiou*, Anastasia Neokleous, Despina Nicolaou, Panagiotis Kolovos Ophthalmos Research and Educational Institute. Nicosia, Cyprus * Corresponding author at Ophthalmos Research and Educational Institute. Morfou 48, Engomi, Nicosia, Cyprus. address: (Dr. Tassos Georgiou) Introduction The Inflammation Research Foundation, Marblehead, MA, supplied the omega-3 fatty acid concentrates for the study. The omega-3 concentrates consisted of purified ethyl esters rich in EPA (400 mg) and DHA (200 mg) per gram for the liquid formulation. Sixteen eyes of 9 patients with retinal dystrophy were treated with 5-10g of EPA/DHA orally in liquid form. Best corrected visual acuity measurements were noted using the ETDRS electronic chart. Clinical examination and OCT scans were performed to exclude any other pathology. Patients were followed up for 6 months every 6 weeks. A blood test to check the AA/EPA ratio was also measured using Gas Chromatography. Methods and Materials Our open pilot study indicates that high-dose omega-3 fatty acids (5 to 10 grams of EPA and DHA per day) represents a potentially new therapeutic approach for the treatment of macular dystrophies. The dose of each patient should be adjusted so that the AA/EPA is less than 2 to have the maximum clinical benefit. There is no cure for macular dystrophies. However, since these appear to be inflammatory-mediated conditions, the use of high- dose anti-inflammatory omega-3 fatty acids may offer a potential long-term management approach. Our working hypothesis is that resolution of inflammation in the eye may be mediated by resolvins, especially those derived from EPA (3,4). The limitations of this preliminary study are (a) the limited number of subjects studied and (b) the lack of a placebo- controlled treatment group. Additional clinical trials to address these limitations are currently in progress. Discussion Retinal Dystrophies refer to a range of eye conditions which cause progressive damage to rod and cone photoreceptors and most patients eventually become blind. Retinitis Pigmentosa is the most common retinal dystrophy. Yoshida et al (1,2) suggested that low grade chronic inflammation may contribute to the disease pathogenesis. Currently there is no treatment to stop progression or improve vision in these patients. We hypothesized that high-dose omega-3 fatty acids may provide improvement of visual function due to its anti-inflammatory effects. This pilot study was done to support that hypothesis. Results Ophthalmos Research and Educational Institute The mean age of patients is 49 years ranging from 18 to 67 years old. Visual acuity ranged from 20/25 to 20/400 with mean of 20/45. Eight right eyes and 8 left eyes. Ten eyes had Retinitis Pigmentosa, 2 eyes had Best disease, 2 eyes had Adult Vitelliform dystrophy and 2 eyes had Cone dystrophy. We used a finger prick test to measure the blood ratio of Arachidonic Acid to Eicosapentaenoic Acid (AA/EPA) for all patients. Figure 1. Visual acuity gain in letters. The eyes that had the greatest gain in vision were those who were taking 8-10g/day. Patients taking 8-10g day had 11.1 letters gain at 6 months and patients taking 5g/day had 6.33 letters gain at 6 months. Average gain is 9.63 letters at 6 months. 1. Yoshida N et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013;120: Yoshida N et al. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2012;120:e Li N et al. Resolvin E1 improves tear production and decreases inflammation in dry eye mouse model. J Ocul Pharmacol Ther 2010; 26: Georgiou T, et al. Pilot study for treating dry age-related macular degeneration (AMD) with high-dose omega-3 fatty acids. Doi.org/ /j.phanu References Figure 2. Visual acuity gain in relation to AA/EPA ratio. Patients who had a ratio of AA/EPA less than 2 gained more letters than patients who had a ratio of >2 Innate immune system